{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:06:47Z","timestamp":1790201207490,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-025-13017-9","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:31:44Z","timestamp":1751538704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient knowledge and acceptance of the upcoming automatic substitution of biological medicines in community pharmacies: survey of Finnish patients with inflammatory bowel disease and psoriasis"],"prefix":"10.1186","volume":"25","author":[{"given":"Essi Elisabeth","family":"Alanne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Aarnio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Timonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katri","family":"H\u00e4meen-Anttila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"13017_CR1","unstructured":"IQVIA. The Impact of Biosimilar Competition in Europe. 2020; Available from: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2021.pdf."},{"key":"13017_CR2","doi-asserted-by":"publisher","first-page":"100075","DOI":"10.1016\/j.medidd.2020.100075","volume":"9","author":"FD Makurvet","year":"2021","unstructured":"Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Med Drug Discov-ery. 2021;9:100075.","journal-title":"Med Drug Discov-ery"},{"key":"13017_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphar.2019.00279","volume":"10","author":"DC Baumgart","year":"2019","unstructured":"Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in Immune-Mediated Inflamma-tory diseases: can biosimilars reduce access inequities?? Front Pharmacol. 2019;10:279.","journal-title":"Front Pharmacol"},{"issue":"9","key":"13017_CR4","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/ard-2022-223696","volume":"82","author":"M Stajszczyk","year":"2023","unstructured":"Stajszczyk M, Obarska I, Jeka S, Batko B. Budget impact analysis and treatment availabilitys with biosimilar TNF inhibitors in rheumatic diseases in poland: real-world evidence using a nationwide database. Ann Rheym Dis. 2023;82(9):1171\u201380.","journal-title":"Ann Rheym Dis"},{"issue":"4","key":"13017_CR5","first-page":"26","volume":"134","author":"M Stajszczyk","year":"2024","unstructured":"Stajszczyk M, Kwiatkowska B, Zuber ZM, Batko B. Access to biologics and Janus kinase inhibitors for treatment of rheumatic diseases in the biosimilars era in poland: a nation-level study. Pol Arch Intern Med. 2024;134(4):26.","journal-title":"Pol Arch Intern Med"},{"key":"13017_CR6","unstructured":"World Health Organization. WHO guideline on country pharmaceutical pricing policies, second edition. 2020. Available from: https:\/\/iris.who.int\/bitstream\/handle\/10665\/335692\/9789240011878-eng.pdf. Cited 2024 Feb 8."},{"key":"13017_CR7","unstructured":"European Medicines Agency. Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf. Cited 2024 Feb 8."},{"issue":"4","key":"13017_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40259-022-00540-y","volume":"36","author":"SV Luukkanen","year":"2022","unstructured":"Luukkanen SV, Tolonen HM, Airaksinen M, Saarukka LSM. The price and market share evolution of the original biologics and their biosimilars in Finland. BioDrugs. 2022;36(4):537\u201347.","journal-title":"BioDrugs"},{"key":"13017_CR9","doi-asserted-by":"publisher","first-page":"625296","DOI":"10.3389\/fphar.2021.625296","volume":"12","author":"S Vogler","year":"2021","unstructured":"Vogler S, Schneider P, Zuba M, Busse R, Panteli D. Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol. 2021;12:625296.","journal-title":"Front Pharmacol"},{"issue":"5","key":"13017_CR10","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s12325-021-01688-9","volume":"38","author":"A Afzali","year":"2021","unstructured":"Afzali A, Furtner D, Melsheimer R, Molloy PJ. The automatic substitution of biosimilars: definitions of interchangeability are not interchangeable. Adv Ther. 2021;38(5):2077\u201393.","journal-title":"Adv Ther"},{"issue":"12","key":"13017_CR11","doi-asserted-by":"publisher","first-page":"e0190147","DOI":"10.1371\/journal.pone.0190147","volume":"12","author":"E Moorkens","year":"2017","unstructured":"Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, et al. Policies for biosimilar uptake in europe: an overview. PLoS ONE. 2017;12(12):e0190147.","journal-title":"PLoS ONE"},{"key":"13017_CR12","doi-asserted-by":"publisher","unstructured":"Barbier L, Mbuaki A, Simoens S, Declerck P, Vulto AG, Huys I. Regulatory Information and Guidance on Biosimilars and Their Use Across Europe: A Call for Strengthened One Voice Messaging. Front Med. 2022;9. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fmed.2022.820755. Cited 2024 Mar 30.","DOI":"10.3389\/fmed.2022.820755"},{"key":"13017_CR13","unstructured":"the Ministry of Social Affairs and Health Decree. on the prescription of medicines1088\/2010. Oikeusministeri\u00f6, Edita Lakitieto Oy; Available from: https:\/\/www.finlex.fi\/fi\/laki\/ajantasa\/2010\/20101088?search%5Btype%5D=pika&search%5Bpika%5D=l%C3%A4%C3%A4kkeen%20m%C3%A4%C3%A4r%C3%A4%C3%A4minen#a22.12.2011459."},{"issue":"6","key":"13017_CR14","first-page":"829","volume":"37","author":"Q Wu","year":"2023","unstructured":"Wu Q, Wang Z, Wang X, Yu H, Sun J. Patients\u2019 Perceptions Biosimilars: Syst Rev BioDrugs. 2023;37(6):829\u201341.","journal-title":"Patients\u2019 Perceptions Biosimilars: Syst Rev BioDrugs"},{"issue":"1","key":"13017_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00296-020-04576-7","volume":"41","author":"C Gasteiger","year":"2021","unstructured":"Gasteiger C, Lobo M, Dalbeth N, Petrie KJ. Patients\u2019 beliefs and behaviours are associated with perceptions of safety and concerns in a hypothetical biosimilar switch. Rheumatol Int. 2021;41(1):163\u201371.","journal-title":"Rheumatol Int"},{"issue":"9","key":"13017_CR16","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/acr.24012","volume":"72","author":"C Gasteiger","year":"2020","unstructured":"Gasteiger C, Jones ASK, Kleinst\u00e4uber M, Lobo M, Horne R, Dalbeth N, et al. Effects of message framing on patients\u2019 perceptions and willingness to change to a biosimilar in a hypothetical drug switch. Arthritis Care Res (Hoboken). 2020;72(9):1323\u201330.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"13017_CR17","doi-asserted-by":"publisher","first-page":"e050949","DOI":"10.1136\/bmjopen-2021-050949","volume":"12","author":"K Kaneko","year":"2022","unstructured":"Kaneko K, Prieto-Alhambra D, Jacklin C, Bosworth A, Dickinson S, Berry S, et al. Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients\u2019 satisfaction: a cross-sectional survey by patient organisations. BMJ Open. 2022;12(2):e050949.","journal-title":"BMJ Open"},{"issue":"5","key":"13017_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med"},{"issue":"1","key":"13017_CR19","first-page":"12","volume":"39","author":"S Reponen","year":"2023","unstructured":"Reponen S, Pohjanoksa-M\u00e4ntyl\u00e4 M, Rutanen J, Mikkonen S, Linden K. Reumapotilaiden N\u00e4kemyksi\u00e4 biologisista L\u00e4\u00e4kkeist\u00e4 Ja Niiden L\u00e4\u00e4kevaihdosta. Dosis. 2023;39(1):12\u201335.","journal-title":"Dosis"},{"key":"13017_CR20","doi-asserted-by":"publisher","unstructured":"Vandenplas Y, Barbier L, Simoens S, Van Wilder P, Vulto AG, Huys I. Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care. Frontiers in Pharmacology. 2022;12. Available from: https:\/\/www.frontiersin.org\/articles\/https:\/\/doi.org\/10.3389\/fphar.2021.789640. Cited 2023 Dec 12.","DOI":"10.3389\/fphar.2021.789640"},{"issue":"1","key":"13017_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/ecco-jcc\/jjw138","volume":"11","author":"L Peyrin-Biroulet","year":"2017","unstructured":"Peyrin-Biroulet L, L\u00f6nnfors S, Roblin X, Danese S, Avedano L. Patient perspectives on biosimilars: A survey by the European federation of crohn\u2019s and ulcerative colitis associations. J Crohns Colitis. 2017;11(1):128\u201333.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"13017_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.18553\/jmcp.2023.29.4.343","volume":"29","author":"A Gibofsky","year":"2023","unstructured":"Gibofsky A, Jacobson G, Franklin A, O\u2019Hara-Levi S, Peyrin-Biroulet L, McGrath M, et al. An online survey among US patients with immune-mediated conditions: attitudes about biosimilars. JMCP. 2023;29(4):343\u20139.","journal-title":"JMCP"},{"issue":"2","key":"13017_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1136\/ejhpharm-2019-001999","volume":"28","author":"CMM Barbosa","year":"2021","unstructured":"Barbosa CMM, Rodr\u00edguez de Castro B, Labeaga Beramendi Y, Terroba Alonso P, Barbaz\u00e1n V\u00e1zquez J. Patient satisfaction survey: substitution of reference etanercept with a biosimilar product. Eur J Hosp Pharm. 2021;28(2):109\u201311.","journal-title":"Eur J Hosp Pharm"},{"issue":"12","key":"13017_CR24","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.dld.2019.08.020","volume":"51","author":"N Petitdidier","year":"2019","unstructured":"Petitdidier N, Tannoury J, de\u2019Angelis N, Gagniere C, Hulin A, Rotkopf H, et al. Patients\u2019 perspectives after switching from Infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study. Dig Liver Disease. 2019;51(12):1652\u201360.","journal-title":"Dig Liver Disease"},{"key":"13017_CR25","unstructured":"Finnish Medicines Agency FIMEA, Social Insurance Institution KELA. Suomen l\u00e4\u00e4ketilasto 2022. Available from: https:\/\/www.julkari.fi\/handle\/10024\/14858922. Cited 9 April 2025."},{"key":"13017_CR26","unstructured":"Fimea. Pharmacies are soon allowed to substitute a biological medicine with a more afford-able alternative - Asset Display Page - Fimea. 2024. Available from: https:\/\/fimea.fi\/en\/-\/pharmacies-are-soon-allowed-to-substitute-a-biological-medicine-with-a-more-affordable-alternative. Cited 2024 Feb 8."},{"key":"13017_CR27","unstructured":"The Goverment\u2019s. proposal to the Parliament for laws to amend the Medicines Act (HE 314\/2022). Available from: https:\/\/www.finlex.fi\/fi\/esitykset\/he\/2022\/20220314."},{"issue":"21\u201322","key":"13017_CR28","first-page":"1012","volume":"77","author":"K Klintrup","year":"2022","unstructured":"Klintrup K, Kastarinen H, Helminen S, Leinonen J, Saastamoinen L. Kela kehottaa: Suosi biosimilaareja, Kun M\u00e4\u00e4r\u00e4\u00e4t biologisia L\u00e4\u00e4kkeit\u00e4. L\u00e4\u00e4k\u00e4rilehti Fi. 2022;77(21\u201322):1012\u20134.","journal-title":"L\u00e4\u00e4k\u00e4rilehti Fi"},{"key":"13017_CR29","unstructured":"The Government\u2019s. proposal to the Parliament for laws to amend the Health Insurance Act and the Medicines Act (HE 100\/2008). Oikeusministeri\u00f6; 2008. Avail-ble from: https:\/\/www.finlex.fi\/fi\/esitykset\/he\/2008\/20080100. Cited 2024 Feb 13."},{"key":"13017_CR30","unstructured":"Medicines Act 395. \/1987 [Internet]. Oikeusministeri\u00f6, Edita Lakitieto Oy;. Available from: https:\/\/www.finlex.fi\/fi\/laki\/ajantasa\/1987\/19870395. Cited 2024 Feb 13."},{"key":"13017_CR31","unstructured":"The University Pharmacy services in. english| Ya.fi. Available from: https:\/\/www.yliopistonapteekki.fi\/fi\/apteekkipalvelut\/pages\/english-aspx. Cited 2024 Feb 9."},{"issue":"2","key":"13017_CR32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/pds.2084","volume":"20","author":"R Heikkil\u00e4","year":"2011","unstructured":"Heikkil\u00e4 R, M\u00e4ntyselk\u00e4 P, Ahonen R. Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland. Pharmacoepidemiol Drug Saf. 2011;20(2):185\u201391.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"13017_CR33","first-page":"rkac099","volume":"6","author":"A Quinlivan","year":"2022","unstructured":"Quinlivan A, Lester S, Barrett C, Whittle S, Rowett D, Black R, et al. Attitudes of Australi-ans with inflammatory arthritis to biologic therapy and biosimilars. Rheumatol Adv Pract. 2022;6(3):rkac099.","journal-title":"Rheumatol Adv Pract"},{"issue":"3","key":"13017_CR34","doi-asserted-by":"publisher","first-page":"otac035","DOI":"10.1093\/crocol\/otac035","volume":"4","author":"A Charabaty","year":"2022","unstructured":"Charabaty A, Schneider B, Zambrano JA, Keefer L. Living with inflammatory bowel Dis-ease: online surveys evaluating patient perspectives on treatment satisfaction and Health-Related quality of life. Crohns Colitis 360. 2022;4(3):otac035.","journal-title":"Crohns Colitis 360"},{"key":"13017_CR35","unstructured":"Jyrkk\u00e4 J, Kokko M. L\u00e4\u00e4kebarometri-v\u00e4est\u00f6kysely. Kyselyiden Toteutus Ja Sis\u00e4lt\u00f6. Finnish Medicines Agency; 2022."},{"issue":"4","key":"13017_CR36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/03007995.2018.1560221","volume":"35","author":"A Teeple","year":"2019","unstructured":"Teeple A, Ginsburg S, Howard L, Huff L, Reynolds C, Walls D, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the united States. Curr Med Res Opin. 2019;35(4):603\u20139.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"13017_CR37","doi-asserted-by":"publisher","first-page":"496","DOI":"10.20344\/amp.10127","volume":"31","author":"A Azevedo","year":"2018","unstructured":"Azevedo A, Bettencourt A, Selores M, Torres T. Biosimilar agents for psoriasis treatment: the perspective of Portuguese patients. Acta Med Port. 2018;31(9):496\u2013500.","journal-title":"Acta Med Port"},{"issue":"6","key":"13017_CR38","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40259-020-00452-9","volume":"34","author":"L Barbier","year":"2020","unstructured":"Barbier L, Simoens S, Vulto AG, Huys I. European stakeholder learnings regarding Bio-similars: part I-Improving biosimilar Understanding and adoption. BioDrugs. 2020;34(6):783\u201396.","journal-title":"BioDrugs"},{"issue":"1","key":"13017_CR39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/17437199.2021.1970610","volume":"17","author":"C Gasteiger","year":"2023","unstructured":"Gasteiger C, den Broeder AA, Stewart S, Gasteiger N, Scholz U, Dalbeth N, et al. The mode of delivery and content of communication strategies used in mandatory and non-mandatory biosimilar transitions: a systematic review with meta-analysis. Health Psychol Rev. 2023;17(1):148\u201368.","journal-title":"Health Psychol Rev"},{"key":"13017_CR40","doi-asserted-by":"crossref","unstructured":"Dillard AJ, Ellis EM. Optimism and its associations with health behavior and responses to health communication. Oxford Research Encyclopedia of Communication (2017, May 24). Retrieved 3 Apr. 2025, from https:\/\/oxfordre.com\/communication\/view\/10.1093\/acrefore\/9780190228613.001.0001\/acrefore-9780190228613-e-342.","DOI":"10.1093\/acrefore\/9780190228613.013.342"},{"key":"13017_CR41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40259-020-00433-y","volume":"34","author":"HP Cohen","year":"2020","unstructured":"Cohen HP, McCabe D. The importance of countering biosimilar disparagement and misinformation. BioDrugs. 2020;34:407\u201314.","journal-title":"BioDrugs"},{"key":"13017_CR42","doi-asserted-by":"publisher","first-page":"e032892","DOI":"10.1136\/bmjopen-2019-032892","volume":"9","author":"H Tolonen","year":"2019","unstructured":"Tolonen H, Airaksinen M, Ruokoniemi P, H\u00e4meen-Anttila K, Shermock KM, Kurki P. Medication safety risks to be managed in National implementation of automatic substitution of biological medicines - a qualitative study. BMJ Open. 2019;9:e032892. https:\/\/doi.org\/10.1136\/bmjopen-2019-032892.","journal-title":"BMJ Open."},{"issue":"3","key":"13017_CR43","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/87551225211052411","volume":"38","author":"BM Morrison","year":"2022","unstructured":"Morrison BM, Boyle TA, Mahaffey T. Awareness, familiarity, and pharmacist trust: A structural equation model analysis. J Pharm Technol. 2022;38(3):174\u201382.","journal-title":"J Pharm Technol"},{"issue":"2","key":"13017_CR44","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/1715163521989760","volume":"154","author":"PAM Gregory","year":"2021","unstructured":"Gregory PAM, Austin Z. Understanding the psychology of trust between patients and their community pharmacists. Can Pharm J. 2021;154(2):120\u20138.","journal-title":"Can Pharm J"},{"issue":"4","key":"13017_CR45","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40259-024-00659-0","volume":"38","author":"C Rieger","year":"2024","unstructured":"Rieger C, Dean JA, Hall L, Vasquez P, Merlo G. Barriers and enablers affecting the Up-take of biosimilar medicines viewed through the Lens of actor network theory: A systematic Re-view. BioDrugs. 2024;38(4):541\u201355.","journal-title":"BioDrugs"},{"issue":"1","key":"13017_CR46","first-page":"36","volume":"39","author":"K Sarnola","year":"2023","unstructured":"Sarnola K, Kauppinen H, Siitonen P. T\u00e4ydennyskoulutus Ja Tiedonl\u00e4hteet biologisista l\u00e4\u00e4k-keist\u00e4. Dosis. 2023;39(1):36\u201349.","journal-title":"Dosis"},{"issue":"1","key":"13017_CR47","first-page":"74","volume":"38","author":"S Kaunisto","year":"2022","unstructured":"Kaunisto S, Siitonen P, Kauppinen H, Sarnola K. Pharmacists\u2019 perceptions about knowledge of biologic medicines and their interchangeability and pharmacist-led substitution. Dosis. 2022;38(1):74\u2013101.","journal-title":"Dosis"},{"key":"13017_CR48","unstructured":"Tolonen H. Towards the high quality of population health surveys. Standardization and quality control. National Public Health Institute; Helsinki, Finland; 2006."},{"key":"13017_CR49","unstructured":"Finnish National Board on Research Integrity TENK. The ethical principles of research with human participants and ethical review in the human sciences in Finland. 2019. Available from: https:\/\/tenk.fi\/sites\/default\/files\/2021-01\/Ethical_review_in_human_sciences_2020.pdf. Cited 2024 Feb 9."},{"key":"13017_CR50","unstructured":"EU General Data Protection Regulation (GDPR). Regulation (EU) 2016\/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95\/46\/EC (General Data Protection Regulation). OJ L Apr 27, 2016. Available from: http:\/\/data.europa.eu\/eli\/reg\/2016\/679\/oj\/fin."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13017-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-025-13017-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-025-13017-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:31:52Z","timestamp":1751538712000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-025-13017-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13017"],"URL":"https:\/\/doi.org\/10.1186\/s12913-025-13017-9","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to the Finnish ethical instructions for non-medical human sciences research, the study did not require an ethical review due to the study design []. Nevertheless, ethical perspectives were considered in the design and implementation of the survey. Participation in the survey was voluntary, and participants were asked for informed consent before taking part in the survey with an electronic checkbox. At the end of the questionnaire, participants were asked if they were willing to provide their contact information for a follow-up study. However, the collected contact information was excluded from the analysis of this study. In the survey, indirect personal data (such as age, gender, health district etc.) and health information (morbidity, medical history) were collected and processed in accordance with the European General Data Protection Regulation [].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"905"}}